Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Feasibility Trial of Post-Transplant Infusion of Allogeneic Regulatory T Cells and Allogeneic Conventional T Cells in Patients With Hematologic Malignancies Undergoing Allogeneic Myeloablative Hematopoietic Cell Transplantation From Haploidentical-Related Donors

NCT01050764 is registered in ClinicalTrials.gov with Everett Meyer as lead sponsor.

NCT NCT01050764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01050764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Feasibility Trial of Post-Transplant Infusion of Allogeneic Regulatory T Cells and Allogeneic Conventional T Cells in Patients With Hematologic Malignancies Undergoing Allogeneic Myeloablative Hematopoietic Cell Transplantation From Haploidentical-Related Donors
Lead sponsor
Everett Meyer
Phase
Phase 1/2
Overall status
Terminated
Start date
June 30, 2009
Completion date
June 30, 2014
Enrollment
10 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute lymphoblastic leukemia (all), acute myelogenous leukemia (aml), chronic lymphocytic leukemia (cll), chronic myelogenous leukemia (cml), leukemia, acute, myelodysplastic syndrome (mds), non-hodgkin lymphoma (nhl)